Beovu (brolucizumab-dbll) is a prescription medication approved by the U.S. Food and Drug Administration to treat wet age-related macular degeneration (AMD). It’s administered by injection into the eye. From its approval in October 2019 to February 2020, doctors have administered about 46,000 Beovu injections.
In February 2020, the American Society of Retina Specialists (ASRS) shared an update with its members about reports of 14 cases of vasculitis in patients who took Beovu. Vasculitis is inflammation of the vascular branches of arteries in the retina. Of those 14 cases, 11 people suffered occlusive retinal vasculitis. Occlusive retinal vasculitis is a condition that happens when blood vessels in the eye become blocked. The condition may lead to blindness. After a month, cases increased to 25 cases of retinal vasculitis. Twenty-one of them involved occlusion.
If Beovu (brolucizumab-dbll) was responsible for your injury, blindness, or other symptoms, you may legally deserve compensation for your losses, which could include:
We know how expensive, emotionally damaging, and physically traumatic injuries like these can be can be. We also know that drug companies must be held responsible for their errors in order to create a safer and more just world. We want to stand up with you against these negligent businesses to make certain that these mistakes don’t harm future patients.
It can be difficult to know if post-medication complications were caused by a defective drug like Beovu. The best way to learn more about your case is to speak with an experienced defective drug attorney about the details of your case.
At Sweeney Merrigan Personal Injury Lawyers, we are dedicated to helping those harmed by negligent medical companies. One of the ways we show our dedication is by offering those affected by Beovu a free, private consultation with one of our attorneys. To schedule your meeting, please contact us today via contact form or call (617) 362-4713.